Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Are the Key Growth Indicators and Market Expansion Estimates for the Neurogenomics Market Through 2029?
The neurogenomics market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to growing demand for genetic testing in neurological disorders, increasing research on brain-behavior-genome links, rising prevalence of neurodegenerative diseases, increasing funding for neuroscience research, and a growing number of biobanks and genomic databases.
The neurogenomics market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing interest in personalized treatments for mental health, increasing use of direct-to-consumer neurogenetic testing, growing adoption of multi-omics approaches, increasing precision neurology initiatives, and increasing adoption of targeted therapies. Major trends in the forecast period include developing artificial intelligence-powered genomic analytics, developing non-invasive diagnostic platforms, integration of multi-omics approaches, integration of genomics in precision neurology, and innovation in neurodegenerative disease modelling.
Get your free report sample today:
Which Key Drivers Are Fueling Growth in the Neurogenomics Market?
The rising prevalence of neurological disorders is expected to propel the growth of the neurogenomics market going forward. Neurological disorders refer to medical conditions that affect the brain, spinal cord, or nerves, leading to symptoms such as muscle weakness, seizures, pain, or cognitive difficulties. The increasing prevalence of neurological disorders is primarily due to lifestyle factors such as poor diet, lack of physical activity, chronic stress, and increasing exposure to environmental toxins. Neurogenomics provides a deeper understanding of the genetic basis of brain function and dysfunction, enabling the identification of causes, improved diagnosis, and targeted treatments for neurological disorders. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, and this number is projected to rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the neurogenomics market.
How Is the Neurogenomics Market Categorized Based on Key Segments?
The neurogenomics market covered in this report is segmented –
1) By Offering: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Software And Services
2) By Application: Variant Discovery, Research Applications, Target Identification, Transcription Factor Binding Analysis, Functional Studies, Clinical Applications
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories
Subsegments:
1) By Next-Generation Sequencing: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, Ribonucleic Acid Sequencing
2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction
3) By Microarray: Deoxyribonucleic Acid Microarray, Ribonucleic Acid Microarray, Protein Microarray
4) By Software And Services: Data Analysis And Interpretation Software, Genomic Data Management Tools, Custom Services, Cloud-Based Platforms And Reporting Tools
Which Emerging Trends Are Shaping the Future of the Neurogenomics Market?
Major companies operating in the neurogenomics market are focusing on developing advanced solutions, such as whole genome sequencing platforms, to enhance the diagnosis and understanding of complex neurological disorders. Whole genome sequencing platforms are tools used to analyze the complete DNA sequence of an individual’s genome, helping identify genetic factors linked to neurological disorders. For instance, in April 2023, Centogene N.V., a Germany-based company that engages in diagnosis and research related to rare diseases, launched CentoGenome, the world’s most comprehensive whole-genome sequencing (WGS) solution for diagnosing rare and neurodegenerative diseases. This platform utilizes PCR-free technology to enable high-quality, unbiased sequencing across complex genetic regions. It enhances variant detection using an advanced bioinformatics pipeline and expert interpretation, identifying nearly all disease-causing variants in a single test. Additionally, it provides integrated, lifelong diagnostic support, including free variant reclassification and confirmatory testing as new scientific knowledge becomes available.
Who Are the Leading Market Participants in the Neurogenomics Market?
Major companies operating in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc, Vigil Neuroscience Inc., PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., Neurogene.
Get the detailed neurogenomics market report today
Which Regions Are Driving the Highest Demand in the Neurogenomics Market?
North America was the largest region in the neurogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment